尊龙凯时

At the core of our platform is a suite of industry-leading foundational AI models, built upon a proprietary biologics database. Guided by emerging therapeutic concepts and disease biology, we continuously advance our AI-driven approaches to address complex biologics design challenges—from conditionally activated antibodies to multispecific T-cell engagers.

We curate a comprehensive, multi-modal biologics database using advanced techniques such as single B-cell sequencing. By intentionally incorporating both positive data and negative outcomes—such as molecules with poor developability—we create a robust foundation for training large-scale generative and predictive models with greater accuracy and relevance.

Trusted by industry partners, we deliver tailored, differentiated solutions to drug discovery challenges once considered intractable. Our comprehensive hit panels are readily engineerable for advanced attributes, opening the door to novel therapeutic opportunities and addressing unmet medical needs.